{
"info": {
"nct_id": "NCT01940172",
"official_title": "A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer",
"inclusion_criteria": "Healthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
"exclusion_criteria": "",
"miscellaneous_criteria": "Inclusion Criteria-If subject:\n\n* Is a women who is at least 18 years of age.\n* Has a negative serum pregnancy test at screening for women of childbearing potential.\n* Pathologically confirmed ovarian cancer (epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer) may have had a maximum of 3 prior systemic chemotherapy regimens (excluding hormonal therapies and investigational agents).\n* Has a performance status of 0 or 1 by the Eastern Cooperative Oncology Group (ECOG) scale.\n* Has a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria AND meet Gynecologic Cancer InterGroup (GCIG) CA 125 criteria.\n* Has a life expectancy of at least 3 months.\n* Has adequate liver, renal, pancreatic, coagulation and bone marrow function.\n\nExclusion Criteria-If subject:\n\n* Has symptomatic or uncontrolled brain metastases requiring current treatment (<8 weeks from last cranial radiation treatment or <4 weeks from last steroid treatment).\n* Has known intolerance to any of the study drugs or any of their excipients.\n* Has known or suspected diagnosis of human immunodeficiency virus (HIV) or chronic active Hepatitis B or C.\n* Has uncontrolled hypertension defined as blood pressure >160/100 mmHg without medication, or not controlled despite medications.\n* Has received systemic chemotherapy, hormonal therapy, immunotherapy, anti-tumor necrosis factor (TNF) therapies, experimental or approved anticancer proteins/antibodies therapy\n\n ≤28 days before enrollment.\n* Has impaired cardiac function or clinically significant cardiac disease including the following:\n\n 1. New York Heart Association Grade III or IV congestive heart failure.\n 2. Myocardial infarction within the last 12 months prior to dosing with birinapant.\n* Has a QT interval corrected for heart rate (QTcB) >480 msec (including subjects on medication). Subjects with a ventricular pacemaker for whom QT interval is not measurable may be eligible.\n* Has a lack of recovery of prior adverse non-hematological events to Grade ≤1 severity (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v4.03) (except alopecia) due to therapy administered prior to the initiation of study drug dosing.\n* Has any concurrent disease and/or medical condition that, in the opinion of the Investigator, would prevent the subject's participation, render the subject at excessive risk (including excessive risks due to the toxicity profile of the planned combination chemotherapeutic regimen), or limit the subject's compliance with the protocol's required evaluations.\n* Has a prior history of cranial nerve palsy.\n* Has autoimmune diseases or inflammatory diseases, for example, active rheumatoid arthritis, active inflammatory bowel disease or any chronic inflammatory conditions.\n* Has pseudomyxoma, mesothelioma, unknown primary tumor, sarcoma, neuroendocrine histology, clear cell or mucinous histology or subjects with borderline ovarian cancer.\n* Requires concomitant chronic use of anti-TNF therapies, corticosteroids or nonsteroidal anti- inflammatory drugs (NSAIDS). Intermittent use (7 or fewer days per 14 days) of corticosteroids as pre-medications is allowed."
},
"inclusion_lines": [
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be FEMALE",
"criterions": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "female"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [],
"miscellaneous_lines": [
{
"line": "* Is a women who is at least 18 years of age.",
"criterions": [
{
"exact_snippets": "women",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected gender",
"expected_value": "female"
}
]
},
{
"exact_snippets": "at least 18 years of age",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* Has a negative serum pregnancy test at screening for women of childbearing potential.",
"criterions": [
{
"exact_snippets": "negative serum pregnancy test",
"criterion": "serum pregnancy test",
"requirements": [
{
"requirement_type": "result",
"expected_value": "negative"
}
]
},
{
"exact_snippets": "women of childbearing potential",
"criterion": "childbearing potential",
"requirements": [
{
"requirement_type": "status",
"expected_value": "women of childbearing potential"
}
]
}
]
},
{
"line": "* Pathologically confirmed ovarian cancer (epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer) may have had a maximum of 3 prior systemic chemotherapy regimens (excluding hormonal therapies and investigational agents).",
"criterions": [
{
"exact_snippets": "Pathologically confirmed ovarian cancer (epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer)",
"criterion": "ovarian cancer type",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": "pathologically confirmed"
},
{
"requirement_type": "subtypes",
"expected_value": [
"epithelial ovarian cancer",
"primary peritoneal cancer",
"fallopian tube cancer"
]
}
]
},
{
"exact_snippets": "may have had a maximum of 3 prior systemic chemotherapy regimens",
"criterion": "prior systemic chemotherapy regimens",
"requirements": [
{
"requirement_type": "maximum number",
"expected_value": {
"operator": "<=",
"value": 3,
"unit": "regimens"
}
}
]
},
{
"exact_snippets": "excluding hormonal therapies and investigational agents",
"criterion": "prior treatments",
"requirements": [
{
"requirement_type": "exclusion",
"expected_value": [
"hormonal therapies",
"investigational agents"
]
}
]
}
]
},
{
"line": "* Has a performance status of 0 or 1 by the Eastern Cooperative Oncology Group (ECOG) scale.",
"criterions": [
{
"exact_snippets": "performance status of 0 or 1 by the Eastern Cooperative Oncology Group (ECOG) scale",
"criterion": "performance status",
"requirements": [
{
"requirement_type": "scale",
"expected_value": "Eastern Cooperative Oncology Group (ECOG)"
},
{
"requirement_type": "value",
"expected_value": [
"0",
"1"
]
}
]
}
]
},
{
"line": "* Has a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria AND meet Gynecologic Cancer InterGroup (GCIG) CA 125 criteria.",
"criterions": [
{
"exact_snippets": "measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria",
"criterion": "measurable disease",
"requirements": [
{
"requirement_type": "criteria",
"expected_value": "Response Evaluation Criteria in Solid Tumors (RECIST) 1.1"
}
]
},
{
"exact_snippets": "meet Gynecologic Cancer InterGroup (GCIG) CA 125 criteria",
"criterion": "CA 125 criteria",
"requirements": [
{
"requirement_type": "criteria",
"expected_value": "Gynecologic Cancer InterGroup (GCIG)"
}
]
}
]
},
{
"line": "* Has a life expectancy of at least 3 months.",
"criterions": [
{
"exact_snippets": "life expectancy of at least 3 months",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "months"
}
}
]
}
]
},
{
"line": "* Has adequate liver, renal, pancreatic, coagulation and bone marrow function.",
"criterions": [
{
"exact_snippets": "adequate liver ... function",
"criterion": "liver function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "adequate ... renal ... function",
"criterion": "renal function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "adequate ... pancreatic ... function",
"criterion": "pancreatic function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "adequate ... coagulation ... function",
"criterion": "coagulation function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "adequate ... bone marrow function",
"criterion": "bone marrow function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "* Has symptomatic or uncontrolled brain metastases requiring current treatment (<8 weeks from last cranial radiation treatment or <4 weeks from last steroid treatment).",
"criterions": [
{
"exact_snippets": "Has symptomatic or uncontrolled brain metastases",
"criterion": "brain metastases",
"requirements": [
{
"requirement_type": "symptomatic",
"expected_value": true
},
{
"requirement_type": "control",
"expected_value": false
}
]
},
{
"exact_snippets": "requiring current treatment",
"criterion": "brain metastases treatment",
"requirements": [
{
"requirement_type": "current",
"expected_value": true
}
]
},
{
"exact_snippets": "<8 weeks from last cranial radiation treatment",
"criterion": "time since last cranial radiation treatment",
"requirements": [
{
"requirement_type": "time since",
"expected_value": {
"operator": "<",
"value": 8,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "<4 weeks from last steroid treatment",
"criterion": "time since last steroid treatment",
"requirements": [
{
"requirement_type": "time since",
"expected_value": {
"operator": "<",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Has known intolerance to any of the study drugs or any of their excipients.",
"criterions": [
{
"exact_snippets": "known intolerance to any of the study drugs",
"criterion": "intolerance to study drugs",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "known intolerance to ... any of their excipients",
"criterion": "intolerance to excipients of study drugs",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Has uncontrolled hypertension defined as blood pressure >160/100 mmHg without medication, or not controlled despite medications.",
"criterions": [
{
"exact_snippets": "uncontrolled hypertension",
"criterion": "hypertension",
"requirements": [
{
"requirement_type": "control",
"expected_value": false
}
]
},
{
"exact_snippets": "blood pressure >160/100 mmHg",
"criterion": "blood pressure",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">",
"value": 160,
"unit": "mmHg"
}
}
]
},
{
"exact_snippets": "blood pressure >160/100 mmHg",
"criterion": "blood pressure",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">",
"value": 100,
"unit": "mmHg"
}
}
]
},
{
"exact_snippets": "without medication",
"criterion": "medication for hypertension",
"requirements": [
{
"requirement_type": "use",
"expected_value": false
}
]
},
{
"exact_snippets": "not controlled despite medications",
"criterion": "hypertension control with medication",
"requirements": [
{
"requirement_type": "control",
"expected_value": false
}
]
}
]
},
{
"line": "* Has received systemic chemotherapy, hormonal therapy, immunotherapy, anti-tumor necrosis factor (TNF) therapies, experimental or approved anticancer proteins/antibodies therapy",
"criterions": [
{
"exact_snippets": "Has received systemic chemotherapy",
"criterion": "systemic chemotherapy",
"requirements": [
{
"requirement_type": "receipt",
"expected_value": true
}
]
},
{
"exact_snippets": "Has received ... hormonal therapy",
"criterion": "hormonal therapy",
"requirements": [
{
"requirement_type": "receipt",
"expected_value": true
}
]
},
{
"exact_snippets": "Has received ... immunotherapy",
"criterion": "immunotherapy",
"requirements": [
{
"requirement_type": "receipt",
"expected_value": true
}
]
},
{
"exact_snippets": "Has received ... anti-tumor necrosis factor (TNF) therapies",
"criterion": "anti-tumor necrosis factor (TNF) therapies",
"requirements": [
{
"requirement_type": "receipt",
"expected_value": true
}
]
},
{
"exact_snippets": "Has received ... experimental or approved anticancer proteins/antibodies therapy",
"criterion": "experimental or approved anticancer proteins/antibodies therapy",
"requirements": [
{
"requirement_type": "receipt",
"expected_value": true
}
]
}
]
},
{
"line": "≤28 days before enrollment.",
"criterions": [
{
"exact_snippets": "≤28 days before enrollment",
"criterion": "time before enrollment",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": "<=",
"value": 28,
"unit": "days"
}
}
]
}
]
},
{
"line": "* Has impaired cardiac function or clinically significant cardiac disease including the following:",
"criterions": [
{
"exact_snippets": "impaired cardiac function",
"criterion": "cardiac function",
"requirements": [
{
"requirement_type": "impairment",
"expected_value": true
}
]
},
{
"exact_snippets": "clinically significant cardiac disease",
"criterion": "cardiac disease",
"requirements": [
{
"requirement_type": "clinical significance",
"expected_value": true
}
]
}
]
},
{
"line": "1. New York Heart Association Grade III or IV congestive heart failure.",
"criterions": [
{
"exact_snippets": "New York Heart Association Grade III or IV congestive heart failure.",
"criterion": "New York Heart Association Grade",
"requirements": [
{
"requirement_type": "severity",
"expected_value": [
"III",
"IV"
]
}
]
},
{
"exact_snippets": "New York Heart Association Grade III or IV congestive heart failure.",
"criterion": "congestive heart failure",
"requirements": [
{
"requirement_type": "severity",
"expected_value": [
"III",
"IV"
]
}
]
}
]
},
{
"line": "2. Myocardial infarction within the last 12 months prior to dosing with birinapant.",
"criterions": [
{
"exact_snippets": "Myocardial infarction within the last 12 months",
"criterion": "myocardial infarction",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 12,
"unit": "months"
}
]
}
}
]
}
]
},
{
"line": "* Has a QT interval corrected for heart rate (QTcB) >480 msec (including subjects on medication). Subjects with a ventricular pacemaker for whom QT interval is not measurable may be eligible.",
"criterions": [
{
"exact_snippets": "QT interval corrected for heart rate (QTcB) >480 msec",
"criterion": "QT interval corrected for heart rate (QTcB)",
"requirements": [
{
"requirement_type": "length",
"expected_value": {
"operator": ">",
"value": 480,
"unit": "msec"
}
}
]
},
{
"exact_snippets": "ventricular pacemaker",
"criterion": "ventricular pacemaker",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Has a lack of recovery of prior adverse non-hematological events to Grade ≤1 severity (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v4.03) (except alopecia) due to therapy administered prior to the initiation of study drug dosing.",
"criterions": [
{
"exact_snippets": "lack of recovery of prior adverse non-hematological events to Grade ≤1 severity (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v4.03)",
"criterion": "recovery of prior adverse non-hematological events",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "Grade (NCI CTCAE v4.03)"
}
}
]
}
]
},
{
"line": "* Has any concurrent disease and/or medical condition that, in the opinion of the Investigator, would prevent the subject's participation, render the subject at excessive risk (including excessive risks due to the toxicity profile of the planned combination chemotherapeutic regimen), or limit the subject's compliance with the protocol's required evaluations.",
"criterions": [
{
"exact_snippets": "Has any concurrent disease and/or medical condition",
"criterion": "concurrent disease and/or medical condition",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "in the opinion of the Investigator, would prevent the subject's participation",
"criterion": "investigator's opinion on participation",
"requirements": [
{
"requirement_type": "opinion",
"expected_value": "would not prevent participation"
}
]
},
{
"exact_snippets": "render the subject at excessive risk (including excessive risks due to the toxicity profile of the planned combination chemotherapeutic regimen)",
"criterion": "excessive risk",
"requirements": [
{
"requirement_type": "risk level",
"expected_value": "not excessive"
}
]
},
{
"exact_snippets": "limit the subject's compliance with the protocol's required evaluations",
"criterion": "compliance with protocol's required evaluations",
"requirements": [
{
"requirement_type": "compliance",
"expected_value": "not limited"
}
]
}
]
},
{
"line": "* Has a prior history of cranial nerve palsy.",
"criterions": [
{
"exact_snippets": "prior history of cranial nerve palsy",
"criterion": "cranial nerve palsy",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* Has autoimmune diseases or inflammatory diseases, for example, active rheumatoid arthritis, active inflammatory bowel disease or any chronic inflammatory conditions.",
"criterions": [
{
"exact_snippets": "Has autoimmune diseases",
"criterion": "autoimmune diseases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "inflammatory diseases",
"criterion": "inflammatory diseases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "active rheumatoid arthritis",
"criterion": "rheumatoid arthritis",
"requirements": [
{
"requirement_type": "activity status",
"expected_value": "active"
}
]
},
{
"exact_snippets": "active inflammatory bowel disease",
"criterion": "inflammatory bowel disease",
"requirements": [
{
"requirement_type": "activity status",
"expected_value": "active"
}
]
},
{
"exact_snippets": "chronic inflammatory conditions",
"criterion": "chronic inflammatory conditions",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Has pseudomyxoma, mesothelioma, unknown primary tumor, sarcoma, neuroendocrine histology, clear cell or mucinous histology or subjects with borderline ovarian cancer.",
"criterions": [
{
"exact_snippets": "Has pseudomyxoma",
"criterion": "pseudomyxoma",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "mesothelioma",
"criterion": "mesothelioma",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "unknown primary tumor",
"criterion": "unknown primary tumor",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "sarcoma",
"criterion": "sarcoma",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "neuroendocrine histology",
"criterion": "neuroendocrine histology",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "clear cell or mucinous histology",
"criterion": "clear cell histology",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "clear cell or mucinous histology",
"criterion": "mucinous histology",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "borderline ovarian cancer",
"criterion": "borderline ovarian cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
}
],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": [
{
"line": "Inclusion Criteria-If subject:",
"criterions": []
},
{
"line": "Exclusion Criteria-If subject:",
"criterions": []
},
{
"line": "* Has known or suspected diagnosis of human immunodeficiency virus (HIV) or chronic active Hepatitis B or C.",
"criterions": [
{
"exact_snippets": "known or suspected diagnosis of human immunodeficiency virus (HIV)",
"criterion": "human immunodeficiency virus (HIV)",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": "known or suspected"
}
]
},
{
"exact_snippets": "known or suspected diagnosis of ... chronic active Hepatitis B",
"criterion": "chronic active Hepatitis B",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": "known or suspected"
}
]
},
{
"exact_snippets": "known or suspected diagnosis of ... chronic active Hepatitis C",
"criterion": "chronic active Hepatitis C",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": "known or suspected"
}
]
}
]
},
{
"line": "* Requires concomitant chronic use of anti-TNF therapies, corticosteroids or nonsteroidal anti- inflammatory drugs (NSAIDS). Intermittent use (7 or fewer days per 14 days) of corticosteroids as pre-medications is allowed.",
"criterions": [
{
"exact_snippets": "Requires concomitant chronic use of anti-TNF therapies",
"criterion": "anti-TNF therapies",
"requirements": [
{
"requirement_type": "use",
"expected_value": "chronic"
}
]
},
{
"exact_snippets": "Requires concomitant chronic use of ... corticosteroids",
"criterion": "corticosteroids",
"requirements": [
{
"requirement_type": "use",
"expected_value": "chronic"
}
]
},
{
"exact_snippets": "Requires concomitant chronic use of ... nonsteroidal anti-inflammatory drugs (NSAIDS)",
"criterion": "nonsteroidal anti-inflammatory drugs (NSAIDS)",
"requirements": [
{
"requirement_type": "use",
"expected_value": "chronic"
}
]
},
{
"exact_snippets": "Intermittent use (7 or fewer days per 14 days) of corticosteroids as pre-medications is allowed",
"criterion": "corticosteroids",
"requirements": [
{
"requirement_type": "use",
"expected_value": "intermittent (7 or fewer days per 14 days)"
}
]
}
]
}
]
}